Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Timothy Aliff"'
Autor:
Giuseppe GIACCONE, David TRENT, John R. STRAWN, Reily SMITH, Thomas J. SMITH, Joan H. SCHILLER, David G. PFISTER, Steven PIANTADOSI, Luke NORDQUIST, Daniel MILTON, Gregory MASTERS, Janessa L. LASKI, David H. JOHNSON, Julie BRAHMER, William PAO, Timothy ALIFF, Sarah TEMIN, Sherman Baker JR, Christopher G. AZZOLI
Publikováno v:
Chinese Journal of Lung Cancer, Vol 13, Iss 3, Pp 171-189 (2010)
Externí odkaz:
https://doaj.org/article/4c40e597843b41f7b295cbd8bfd46afe
Autor:
Christopher G. Azzoli, Timothy Aliff, Thomas J. Smith, William Pao, Reily Smith, Daniel T. Milton, Luke Nordquist, David H. Johnson, Julie R. Brahmer, David Trent, David G. Pfister, Steven Piantadosi, Giuseppe Giaccone, Joan H. Schiller, Sherman Baker, Gregory A. Masters, Janessa L. Laskin, John R. Strawn, Sarah Temin
Publikováno v:
Zhongguo fei ai za zhi = Chinese journal of lung cancer, vol 13, iss 3
Azzoli, CG; Baker, S; Temin, S; Pao, W; Aliff, T; Brahmer, J; et al.(2010). American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. Chinese Journal of Lung Cancer, 13(3), 171-189. doi: 10.3779/j.issn.1009-3419.2010.03.15. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3nh4153x
Chinese Journal of Lung Cancer, Vol 13, Iss 3, Pp 171-189 (2010)
Azzoli, CG; Baker, S; Temin, S; Pao, W; Aliff, T; Brahmer, J; et al.(2009). American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 27(36), 6251-6266. doi: 10.1200/JCO.2009.23.5622. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3fh1q3jc
Azzoli, CG; Baker, S; Temin, S; Pao, W; Aliff, T; Brahmer, J; et al.(2010). American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. Chinese Journal of Lung Cancer, 13(3), 171-189. doi: 10.3779/j.issn.1009-3419.2010.03.15. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3nh4153x
Chinese Journal of Lung Cancer, Vol 13, Iss 3, Pp 171-189 (2010)
Azzoli, CG; Baker, S; Temin, S; Pao, W; Aliff, T; Brahmer, J; et al.(2009). American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 27(36), 6251-6266. doi: 10.1200/JCO.2009.23.5622. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3fh1q3jc
The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was n
Autor:
Y. B. Su, Andrew J. Zahalsky, Michael J. Zelefsky, Ashok R. Shaha, Jatin P. Shah, Dennis H. Kraus, Michael N. Needle, David G. Pfister, Eric Lis, Suzanne L. Wolden, Simone Lake, Timothy Aliff
Publikováno v:
Journal of Clinical Oncology. 24:1072-1078
Purpose Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both chemotherapy and radiotherapy. We conducted a pilot phase II study of a new com
Autor:
David Trent, David H. Johnson, Thomas J. Smith, Timothy Aliff, Gregory A. Masters, Luke Nordquist, William Pao, Janessa L. Laskin, Sarah Temin, Daniel T. Milton, Reily Smith, Giuseppe Giaccone, Christopher G. Azzoli, Sherman Baker, David G. Pfister, Joan H. Schiller, Steven Piantadosi, John R. Strawn, Julie R. Brahmer
Publikováno v:
Azzoli, CG; Temin, S; Aliff, T; Baker, S; Brahmer, J; Johnson, DH; et al.(2011). 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 29(28), 3825-3831. doi: 10.1200/JCO.2010.34.2774. UCLA: Retrieved from: http://www.escholarship.org/uc/item/33n997w1
Purpose An American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56f87c2ac5814723145ebe0b2005ec93
http://www.escholarship.org/uc/item/33n997w1
http://www.escholarship.org/uc/item/33n997w1
Autor:
Richard J. Wong, William L. Gerald, Matthew G. Fury, Timothy Aliff, Andrew J. Zahalsky, Martin Fleisher, Lucy E. Hann, Eric Lis, David G. Pfister, Ennapadam Venkatraman
Publikováno v:
Investigational new drugs. 25(2)
SU5416 (semaxanib) is a synthetic small molecule inhibitor of the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2). This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recu
Autor:
Denise Horgan, Timothy Aliff, Joseph G. Jurcic, Peter Maslak, David A. Scheinberg, Steven E. Kossman, Nicole Lamanna, Stanley R. Frankel, Mark Weiss
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(7)
Purpose: Purine analogs and alkylators are important agents in the treatment of chronic lymphocytic leukemia (CLL). Previously, combinations of fludarabine and chlorambucil were abandoned because of increased toxicity from overlapping myelosuppressio
Autor:
Matthew Fury, Andrew Zahalsky, Richard Wong, Ennapadam Venkatraman, Eric Lis, Lucy Hann, Timothy Aliff, William Gerald, Martin Fleisher
Publikováno v:
Investigational New Drugs; Apr2007, Vol. 25 Issue 2, p165-172, 8p